Form D · Biotechnology
Aardvark Therapeutics, Inc.
San Diego, CA · CIK 0001774857
Offering snapshot reported May 15, 2024 · SEC filing
- Reported sold
- $85M Offering amount: $85M
- Investors reported
- 31 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 1, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 15, 2024 | Initial | $84,999,982 | No comparison | 31 | SEC filing |
| Jun 7, 2021 | Initial | $9,060,000 | No comparison | Not reported | SEC filing |
| May 24, 2019 | Initial | $9,000,003 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.7M
- Finders' fees
- $0
- Form D file number
- 021-513397
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Cantor Fitzgerald & Co. | 134 |
Source: Form D, filed May 15, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jerel Banks | Director |
| Jeffrey Chi | Director |
| Zachary Hornby | Director |
| Henry Ji | Director |
| Tien Li Lee | Director, Executive |
| Bob Shin | Director |
| Nelson Sun | Executive |
| Victor Tong | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4747 Executive Drive Suite 1020
San Diego, CA, 92121
San Diego, CA, 92121